| Budget Amount *help |
¥17,160,000 (Direct Cost: ¥13,200,000、Indirect Cost: ¥3,960,000)
Fiscal Year 2022: ¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2021: ¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2020: ¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2019: ¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
|
|---|
| Outline of Final Research Achievements |
Studies using HLA polymorphism-transgenic mice have provided important insights into the disease mechanisms of abacavir hypersensitivity and flucloxacillin hepatotoxicity. In particular, in the abacavir hypersensitivity model, suppression of immune activation prevents the onset of the disease, which may explain the absence of cases in HLA polymorphism carriers in the clinical setting. In vitro/in silico analysis showed that there may be characteristic differences in the maturation process in the endoplasmic reticulum between risk and non-risk HLA polymorphisms. The in vitro/in silico analysis showed that there may be characteristic differences in the maturation process in the endoplasmic reticulum between risk and non-risk polymorphisms.
|
